NCT03955939: A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

NCT03955939
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have progressed on at least 1 line of endocrine therapy & 1 CDK4/6 inhibitor
Exclusions: Patients who have had prior chemotherapy for metastatic breast cancer
https://ClinicalTrials.gov/show/NCT03955939

Comments are closed.

Up ↑